Navigation Links
Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
Date:10/22/2010

NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced the commencement of a tender offer by its wholly owned subsidiary, Parker Tennessee Corp., for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.  The tender offer is being made pursuant to an Offer to Purchase, dated October 22, 2010, and in connection with the previously announced Agreement and Plan of Merger, dated October 11, 2010, by and among Pfizer, Parker Tennessee Corp. and King.  

(Photo:  http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

Today, Pfizer and Parker Tennessee Corp. will file with the U.S. Securities and Exchange Commission (the "SEC") a Tender Offer Statement on Schedule TO, containing the Offer to Purchase, form of Letter of Transmittal and related tender offer documents, which set forth in detail the terms and conditions of the tender offer.  King will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 setting forth in detail, among other things, the unanimous recommendation of King's Board of Directors that King's shareholders accept the tender offer, tender their shares pursuant to the tender offer and, if required by applicable law, approve the Agreement and Plan of Merger and the transactions contemplated thereby.  These documents will be mailed to all King shareholders of record.

The tender offer is scheduled to expire at 12:00 midnight, New York City
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
2. Biocon and Pfizer Enter Into Global Commercialization Agreement
3. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
4. Pfizer Completed Acquisition of FoldRx
5. Pfizer To Review Strategic Alternatives For Capsugel
6. Pfizer Offers First 500,000 Consumers Free Advil® to Launch Medicine Cabinet Cleanout Campaign
7. Pfizer Invites Public to View and Listen to Webcast of November 2 Conference Call With Analysts
8. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
9. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
10. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
11. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... CANTEL MEDICAL CORP. (NYSE: CMN ) ... per diluted share, on a 24% increase in sales to a ... compares with net income of $4,274,000, or $0.25 per diluted share, ... 2010.  For the nine months ended April 30, 2011, the Company ...
... Pa., June 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical ... treat cancer, today announced the appointment of Mr. Jonathan ... and vice president of corporate development. ... of corporate development and finance experience.  He has led ...
Cached Medicine Technology:Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:9/2/2014)... New York, New York (PRWEB) September 02, 2014 ... metal-on-metal version of the DePuy Pinnacle hip implant ... jury selection begins today in the U.S. District ... reports. According to court documents, Johnson & Johnson ... 6,000 lawsuits that allege the all-metal hip caused ...
(Date:9/2/2014)... Raton, FL (PRWEB) September 02, 2014 ... audience targeting and multi-channel email marketing is pleased to ... the market, Firearms & Freedom as well ... online properties represent more than one million concerned Americans ... display advertising. , “We are honored to continue ...
(Date:9/2/2014)... research shows a novel polypill increases patient adherence ... heart attack, according to new study results reported ... 2014 in Barcelona, Spain. According to Principal Investigator ... Heart at Icahn School of Medicine at Mount ... de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, ...
(Date:9/2/2014)... San Diego School of Medicine have identified an enzyme ... findings, reported in the current issue of PNAS, offer ... worldwide. An estimated 40,000 women in America will die ... Cancer Society. , "The take-home message of the study ... breast cancer metastasis through a pathway regulated by an ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... taken the National Polio Eradication Initiatives and now in ... Days (NIDs) have planned to immunize 22 million children ... ,Government of Bangladesh will carry out the initiatives ... (WHO), Rotary International and the U.S. Centers for Disease ...
... announced that, a novel treatment for brain tumors has ... as 'Oncophage' treatment, is aimed at tackling an aggressive ... of California, are at the helm of this research. ... from a portion of a patient's tumor. After breaking ...
... at least five times a year have more health problems ... ,And people with a severe gambling addiction are ... increased heart rate, angina and liver disease when compared to ... ,“One of the questions that has never been answered is ...
... women put on as they age, according to a finding ... doctor.//,In a study that followed more than 68,000 US women ... of Case Western Reserve University in Cleveland found that women ... weight during middle age. ,The findings were published in ...
... to the remedy of choice to treat chronic constipation.//A ... claims that, it is far more superior in effectiveness ... chronic constipation do not seem to offer the same ... disorder, affecting the intestinal tract .Today, its estimated that ...
... has found anti-clotting drug called bivalirudin (Angiomax) that beats ... coronary syndromes such as heart// attacks. This new blood ... from acute coronary syndromes. ,The Results of ... trial’ were published in November issue of the New ...
Cached Medicine News:Health News:Odds Are That Gamblers Have More Health Problems 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx ... the world's smallest dual-chamber ... advanced pacemaker technology, including ... algorithm, the first U.S. ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: